(Q34168983)

31 July 2017

1 reference

title

S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges (English)

1 reference

31 July 2017

1 reference

Johannes Carl Christoph Lenz

series ordinal

1

1 reference

31 July 2017

Jürgen Kurt Rockstroh

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

8 March 2011

1 reference

Expert Opinion on Investigational Drugs

31 July 2017

published in

1 reference

31 July 2017

volume

20

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

537-548

1 reference

Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562189

Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562189

Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562189

Integrase inhibitors to treat HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562189

Retroviral DNA integration: reaction pathway and critical intermediates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562189

Novel integrase inhibitors for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562189

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562189

Resistance to HIV-1 integrase inhibitors: A structural perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562189

Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562189

HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562189

Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562189

Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562189

Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562189

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562189

10.1517/13543784.2011.562189

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference